Onconetix, Inc. (ONCO)
| Market Cap | 81.07K -97.5% |
| Revenue (ttm) | 735,198 -61.8% |
| Net Income | -10.03M |
| EPS | -30.04 |
| Shares Out | 69.29K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 676,801 |
| Open | 1.250 |
| Previous Close | 1.260 |
| Day's Range | 1.160 - 1.270 |
| 52-Week Range | 0.911 - 382.500 |
| Beta | 3.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About ONCO
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Bl... [Read more]
Financial Performance
In 2025, Onconetix's revenue was $815,371, a decrease of -67.70% compared to the previous year's $2.52 million. Losses were -$15.53 million, -73.63% less than in 2024.
Financial StatementsNews
Onconetix Inc trading halted, news pending
19:50 EDT Onconetix (ONCO) Inc trading halted, news pending
Onconetix announces 1-for-10 reverse stock split
Onconetix (ONCO) announced that its board of directors has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern…
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and com...
Realbotix expects transaction with Onconetix to close by October
Realbotix (XBOTF) provided an update on its previously announced transaction to list Realbotix LLC on the Nasdaq Capital Market via a reverse takeover transaction with Onconetix (ONCO). The proposed t...
Realbotix Provides Update on Nasdaq Listing
LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a leading AI humanoid robot manufacturer for social tasks, is pleased ...
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
New Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion A...
Onconetix Quarterly report: Q1 2026
Onconetix has published its Q1 2026 quarterly earnings report on May 13, 2026.
Onconetix Earnings release: Q1 2026
Onconetix released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Onconetix Registration statement: Registration filing
Onconetix filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Onconetix files to sell 25M shares of common stock for holders
16:12 EDT Onconetix (ONCO) files to sell 25M shares of common stock for holders
Onconetix Registration statement: Registration filing
Onconetix filed a registration statement on April 28, 2026, providing details about a securities offering with the SEC.
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbot...
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a su...
Onconetix CEO Karina Fedasz to step down, David White to succeed
Onconetix (ONCO) announced the appointment of David White as CEO, effective March 18 and the appointment of Sammy Dorf as a member of the company’s board of directors and the…
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconet...
Onconetix Proxy statement: Proxy filing
Onconetix filed a proxy statement on March 30, 2026, providing details for shareholder voting and corporate governance matters.
Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration
Realbotix Humanoid Robot — Ericsson's First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson's U.S. Headquarters; Onconetix Has Entere...
Onconetix Inc trading halted, news pending
19:50 EDT Onconetix (ONCO) Inc trading halted, news pending
Onconetix announces 1-for-5 reverse stock split
Onconetix (ONCO) announced that its board of directors has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern…
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split
CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and c...
Onconetix Proxy statement: Proxy Filing
Onconetix filed a proxy statement on March 18, 2026, providing details for shareholder voting and corporate governance matters.
Onconetix Annual report: Q4 2025
Onconetix has published its Q4 2025 annual report on March 13, 2026.
Onconetix to acquire Realbotix LLC in all-stock transaction
Onconetix (ONCO) and Realbotix LLC (XBOTF) announced the signing of a definitive share exchange agreement pursuant to which Onconetix will acquire 100% of the issued and outstanding equity interests o...
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company
A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, ...
Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer
LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a leader in AI-powered humanoid robots, announces it has entered into ...